drugset / Trial / NCT01937559

Topical Tranexamic Acid (TXA) in Joint Arthroplasty

NCT01937559 ↗

Phase 4 Completed 188 enrolled The Hawkins Foundation
RandomizedParallel-groupDouble-blindTreatment

Summary

The objective of this study is to evaluate the efficacy of topical tranexamic acid (TXA) in decreasing blood loss following both shoulder arthroplasty and primary total hip arthroplasty. TXA functions to decrease blood loss by affecting the blood clotting system within the body. The investigators hypothesize that topical application of TXA prior to closure reduces postoperative bleeding as measured by absolute changes in postoperative hemoglobin levels and surgical drain output. In addition, use of topically applied tranexamic acid may reduce the need for transfusions, the rates of hematomas, infections, and length of hospital stay.

Timeline

Start
2013-04
Primary completion
2018-06
Completion
2018-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Tranexamic Acid Small molecule 1.5 g Topical

Indications